New e. coli vaccine enters first human safety trial
NCT ID NCT07122986
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
Pfizer is testing several experimental vaccines designed to protect against E. coli bacteria. This early-stage study involves 310 healthy adults aged 18 to 64. The main goal is to check if the vaccines are safe and tolerable, not yet whether they work. Participants will receive two shots six months apart and be monitored for side effects like injection-site pain, fever, and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alliance for Multispecialty Research, LLC
RECRUITINGKnoxville, Tennessee, 37909, United States
-
Alliance for Multispecialty Research, LLC
RECRUITINGKnoxville, Tennessee, 37920, United States
-
Anaheim Clinical Trials, LLC
RECRUITINGAnaheim, California, 92801, United States
-
CTI Clinical Research Center
RECRUITINGCincinnati, Ohio, 45212, United States
-
Diablo Clinical Research, Inc.
RECRUITINGWalnut Creek, California, 94598, United States
-
Miami Eye Institute
RECRUITINGHollywood, Florida, 33024, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
Orange County Research Center
RECRUITINGLake Forest, California, 92630, United States
-
Research Centers of America
RECRUITINGHollywood, Florida, 33024, United States
-
Senders Pediatrics
RECRUITINGSouth Euclid, Ohio, 44121, United States
-
University Eye Specialists, P.C. (Ophthalmologist)
RECRUITINGMaryville, Tennessee, 37803, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
E. coli vaccine
What this could lead to
If this vaccine proves safe and effective, it could help prevent E. coli infections, which can cause severe diarrhea and kidney damage.
What could go wrong
This is an early Phase 1 trial focused only on safety in healthy adults. It is too soon to know if the vaccine actually prevents infection, and side effects are possible.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.